Fig. 5

METTL3 upregulates MYC expression through MYC m6A methylation and reduces the sensitivity of Molm13 cells to AraC. A, MYC expression in the bone marrow samples of AML patients (n = 35) and healthy individuals (n = 35) determined by RT-qPCR. B, MYC expression in HS-5, HL-60, Molm13, HL-60 R, and Molm13 R cells measured by RT-qPCR. Molm13 cells were treated with oe-METTL, and Molm13 R cells were treated with sh-METTL. C, MYC expression in Molm13 and Molm13 R cells measured by RT-qPCR. D, The m6A modification level in Molm13 and Molm13 R cells with methylene blue staining as control detected by Dot blot assay. E, Me-RIP and RT-qPCR quantification of the MYC-modified m6A level. Molm13 cells were treated with AraC (2 μM) + oe-METTL3 + sh-MYC, and Molm13 R cells were treated with AraC (2 μM) + sh-METTL3 + oe-MYC. F, MYC expression in Molm13 and Molm13 R cells measured by RT-qPCR. G, Viability of Molm13 and Molm13 R cells evaluated by CCK-8 assay. H, Apoptosis of Molm13 and Molm13 R cells detected by flow cytometry. I, Expression of Bcl-2, Bax, and cleaved caspase-3 protein in Molm13 and Molm13 R cells determined using Western blot analysis. * p < 0.05. Cell experiments were performed three times independently